# Endo Rule Out Hypothyroidism Before Lipid Treatment

> Rules out hypothyroidism as a secondary cause of hyperlipidemia prior to initiating lipid-lowering therapy. Triggered by patient presentation with hyperlipidemia, consideration of starting lipid-lowering medication, or assessment of secondary causes of dyslipidemia.

- Skill: `dromlakhani/endo-rule-out-hypothyroidism-before-lipid-treatment` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-rule-out-hypothyroidism-before-lipid-treatment`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-rule-out-hypothyroidism-before-lipid-treatment/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-rule-out-hypothyroidism-before-lipid-treatment

---


# Rule out hypothyroidism as cause of hyperlipidemia before lipid-lowering treatment

## STEP 1 — Gather Information
Order serum TSH to evaluate for hypothyroidism as a potential cause of hyperlipidemia.

## STEP 2 — Rule In / Rule Out
If TSH is within normal limits, rule out hypothyroidism as the cause of hyperlipidemia; if TSH is elevated, rule in hypothyroidism.

## STEP 3 — Classify or Stratify
If hypothyroidism is ruled in (TSH elevated), classify as overt (TSH ≥10 mIU/L) or subclinical (TSH between upper limit of normal and 10 mIU/L).

## STEP 4 — Decide
If hypothyroidism is confirmed (overt or subclinical with associated hyperlipidemia), initiate levothyroxine therapy and reassess lipid panel after euthyroidism before considering lipid-lowering treatment.

## Clinical Guardrails / Mimics / Pitfalls
Do not initiate lipid-lowering therapy without first ruling out hypothyroidism, as treating the thyroid disorder may resolve hyperlipidemia and avoid unnecessary medication; mimics include other secondary causes (e.g., nephrotic syndrome, medications) but hypothyroidism is a common and treatable cause.

## Concrete Clinical Example
A 55-year-old woman with new hyperlipidemia (LDL-C 190 mg/dL, TG 220 mg/dL) and fatigue has TSH 12.5 mIU/L; after levothyroxine normalization, lipids improve to LDL-C 110 mg/dL, TG 150 mg/dL, avoiding statin initiation.

**Source:** Lipid Management in Patients with Endocrine Disorders, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674